Case Study

DB Ashbourne Limited has been acquired by Ethypharm S.A

The shareholder of DB Ashbourne Limited (DBA) has sold the company to Ethypharm S.A. for an undisclosed consideration.

DBA currently markets and supplies a range of prescription-only medicines to the UK market, generating significant savings for the National Health Service (NHS) and has an exciting pipeline of products in development which will be supplemented with a wide range of additional products from the Ethypharm pipeline.

Ethypharm S.A. is a France-based company engaged in developing, manufacturing and licensing pharmaceutical products. Through the acquisition of DBA, Ethypharm continues to implement its strategy to develop a direct commercial presence in key territories in Europe to market central nervous system products, with a particular focus on pain and innovative treatments for addictions. DBA provides a pivotal platform to generate revenues in the important UK market and this acquisition, along with the deployment of its own commercial operations in France and Germany, will generate a large turnover.

“I am delighted to welcome the DBA team to the Ethypharm group. The acquisition of DBA is a significant step forward for us. The know-how and expertise of both companies are totally complementary and synergistic and DBA offers a great platform to launch products from our own pipeline,” declared Hugues Lecat, CEO of Ethypharm.

Oaklins Cavendish, based in the UK, advised the seller in this transaction.

Tombstone image for DB Ashbourne Limited has been acquired by Ethypharm S.A

KEY DEAL CONTACTS

Gordon Hamilton

United Kingdom

Partner

VIEW PROFILE

Caroline Belcher

United Kingdom

Partner

VIEW PROFILE